Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
This report offers strategic insights into the overall AML therapeutics market along with the market size and estimates for the duration 2020 to 2030.
The research study covers in-depth analysis of market segments based on drug type (chemotherapy drugs and pipeline drugs) and different geographical regions.
Companies Mentioned
- Abbott Laboratories
- Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical)
- Boehringer Ingelheim GmbH
- Bristol Myers Squibb
- Celegene Corporation
- Cephalon Inc.
- Eisai Co. Ltd.
- Eli Lilly and Company
- Genzyme Corporation (A subsidiary of Sanofi S.A.)
- Jazz Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
Acute myeloid leukemia (AML) is type of blood and bone marrow cancer characterized by abnormal production of myeloid blasts in the bone marrow and peripheral blood. Rising incidence of AML, higher number of unmet needs, expected launch of ideal molecules and technological advances are prime factors that driving the growth of AML therapeutics market globally.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global AML therapeutics market. Pipeline analysis and global epidemiology data has been included in report.
Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global AML therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global AML therapeutics market. In-depth competitive environment analysis and historical years (2019) market size data are also provided in the report.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Acute Myeloid Leukemia (AML) Therapeutics market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Acute Myeloid Leukemia (AML) Therapeutics market?
- Which is the largest regional market for Acute Myeloid Leukemia (AML) Therapeutics market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Acute Myeloid Leukemia (AML) Therapeutics market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Acute Myeloid Leukemia (AML) Therapeutics market worldwide?
Key Topics Covered:
1. Preface
2. Executive Summary
3. Acute Myeloid Leukemia (AML) Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Acute Myeloid Leukemia (AML) Therapeutics Market Vendors
3.2. Strategies Adopted by Acute Myeloid Leukemia (AML) Therapeutics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Acute Myeloid Leukemia (AML) Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Acute Myeloid Leukemia (AML) Therapeutics Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Cell Culture Vaccines
5.3.1.1. Cytarabine
5.3.1.2. Anthracyclines
5.3.1.3. Etoposide
5.3.1.4. Others
5.3.2. Pipeline Drugs
6. North America Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
7. UK and European Union Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
8. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
9. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
10. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, 2020-2030, USD (Million)
11. Company Profile
For more information about this report visit https://www.researchandmarkets.com/r/3vgdwa-myeloid?w=12
